Search

Frank Friedersdorff,1,2,* Beatriz Banuelos-Marco,1,2,* Marie-Therese Koch,1,3 Nils Lachmann,1,4 Anna Bichmann,5,6 Kurt Miller,1,2 Ricardo Gonzalez,1,2 Dominik Müller,1,3 Anja Lingnau1,2 1Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; 2Berlin Institute of Health, Clinic of Urology and Paediatric Urology, Berlin, Germany; 3Berlin Institute of Health, Department of Paediatric Gastroenterology, Nephrology and Metabolic Disorders, Berlin, Germany; 4Berlin Institute of Health, Institute of Transfusion Medicine, Berlin, Germany; 5Charité – Department of Anesthesiology and Operative Intensive Care Medicine, Campus Charité Mitte, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany; 6Berlin Institute of Health, Berlin, Germany*These authors contributed equally to this workCorrespondence: Frank FriedersdorffCharité – Universitätsmedizin Berlin, Charitéplatz 1, Berlin, 10117, GermanyTel +4930450615219Email frank.friedersdorff@charite.dePurpose: The aim of this study was to identify factors impacting recipient sensitization rates and paediatric renal transplant patient outcomes.Patients and Methods: For this purpose, a retrospective analysis of 143 paediatric renal transplants was carried out. This included the evaluation of patient’s and donor’s demographic data, HLA mismatches, immunosuppressive therapy, rejection episodes, panel reactive antibody (PRA) and post-transplant lymphoproliferative disease (PTLD).Results: The mean patient age at the point of transplant receival was 11.5 years with a mean follow up time of 9.33± 5.05 years. It was noted that graft survival rates for donors over 59 years had the worst outcome. HLA match did not show statistically significant influence on graft outcome. Graft survival for more than one biopsy-proven rejection was also significantly shorter (p=0.008). PRA were found in 28% of the recipient’s post-transplantation and showed association with lower graft survival rates (p< 0.001). In the present study, 22.7% (5/22) of the patients with EBV infections presented a PTLD.Conclusion: In conclusion, good graft survival with reduced sensitization for future transplantations and minimize the risk of PTLD, can be ensured through a balance between donor age, HLA match and condition of the recipient should be sought. Furthermore, paediatric patients should preferably receive organs from donors between the age of 10 and 59. EBV infection could be a relevant factor for developing PTLD.Keywords: paediatric transplantation, immunological risk factors, graft survival, immunosuppression, kidney transplant, donor statistic

Mathieu Grivet-Seyve,1 Francine Santoro,2 Nadège Lachmann2 1Galderma Research and Development, Sophia Antipolis, France; 2Galderma Research and Development, Egerkingen, Switzerland Background/objective: Rosacea-prone sensitive skin requires high sun-protection factor (SPF) moisturizers. This study evaluated Daylong Extreme SPF 50+ lotion, a novel cream containing five ultraviolet filters, two emollients, and three skin conditioners.Subjects and methods: This was an open-label, single-center study. On day 1, before treatment, subjects answered a questionnaire on their skin conditions and sunscreen habits, and both subjects and dermatologist evaluated skin status. Subjects applied the product once daily in the morning to the face for 21 days, and after approximately 3–5 minutes they assessed tolerability and short-term cosmetic acceptability in a questionnaire and daily diary. On day 22, the dermatologist and subjects evaluated skin status for long-term tolerance and cosmetic acceptability.Results: The study enrolled 44 individuals (mean age 58.8 years, 91% female). At baseline, most subjects (39 of 44) showed erythema, and ~30% showed dryness and scaling. Dermatologists noted four cases of pustules and one case of papules. After 21 days’ treatment with the product, the dermatologist reported significantly less erythema, dryness and scaling, three cases of pustules and two cases of papules. At baseline, ~75% of subjects noted a feeling of dryness, >50% reported tension, and nearly 25% reported tickling. After using the product for 21 days, subjects reported significantly less tension, dryness, and tickling. Some subjects noted itching and burning before and after using the product. One subject noted papules during treatment. Most subjects said that the product was pleasant, did not irritate the skin or cause stinging/burning, was easy to apply, quickly absorbed, and nongreasy, improved skin moisturization, helped prevent sun-provoked facial redness, did not worsen rosacea, and was easily incorporated into their skincare regimen. Half would switch to the product, and 80% of subjects would buy and recommend the product.Conclusion: The product was well tolerated in rosacea-prone subjects, producing objective and subjective improvements in skin status and symptoms. Keywords: rosacea, photodamage, UV light, sensitive skin, patient-reported outcomes, moisturizer